GSK and Sanofi Seek Regulatory Authorization for COVID-19 Vaccine | Financial Buzz

GSK and Sanofi Seek Regulatory Authorization for COVID-19 Vaccine

Sanofi (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) report intent to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.  The Sanofi-GSK booster vaccine has provided a significant increase in neutralizing antibodies of 18- to 30-fold across vaccine platforms and age groups.  Thomas Triomphe, Executive Vice President, Sanofi Vaccines, said: “We’re very pleased with these data, which confirm our strong science and the benefits of our COVID-19 vaccine. The Sanofi-GSK vaccine demonstrates a universal ability to boost all platforms and across all ages. We also observed robust efficacy of the vaccine as a primary series in today’s challenging epidemiological environment. No other global Phase 3 efficacy study has been undertaken during this period with so many variants of concern, including Omicron, and these efficacy data are similar to the recent clinical data from authorized vaccines.”

Roger Connor, President of GSK Vaccines, said: “The evolving epidemiology of COVID-19 demonstrates the need for a variety of vaccines. Our adjuvanted protein-based vaccine candidate uses a well-established approach that has been applied widely to prevent infection with other viruses including pandemic flu. We are confident that this vaccine can play an important role as we continue to address this pandemic and prepare for the post-pandemic period.”

Opt-into our eNewsletter NOW! For the Latest Trending Financial News Topics in Cannabis, Tech, Biotechs, Precious Metals, Energy, Renewable Energy and much more!